Physician profile
Kenneth J Fish
NPI 1912972423
$2,576.21
in general payments reported to CMS, 2019-2025
21 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $146 · 2021: $189 · 2022: $528 · 2023: $448 · 2024: $423 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $406.06 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $386.97 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $300.65 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $294.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.46 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $228.36 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $118.94 | 2022-2024 | Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $79.15 | 2019-2021 | |
| Abbvie INC. | $77.81 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $75.33 | 2019 | |
| Exact Sciences Corporation | $73.40 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $67.36 | 2019-2023 | |
| Amgen INC. | $56.25 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $33.86 | 2019-2025 | |
| Amarin Pharma, INC. | $26.98 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $20.47 | 2023 | Eliquis |
| Xeris Pharmaceuticals, INC. | $20.21 | 2024 | Keveyis |
| Kowa Pharmaceuticals America, INC. | $18.25 | 2020 | |
| Allergan, INC. | $16.42 | 2020 | |
| Grifols USA, LLC | $15.84 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.96 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.